• PREVAPIX-ALL Open label randomized controlled trial in VTE prevention in children with ALL and LLy and the presence of a CVC, using a DOAC (apixaban) during asparaginase containing induction therapy.• Ages 1–18 years old treated with PEG-asparaginase during induction therapy and presence of a CVC. Here, ASPG is linked to acute lymphoblastic leukemia.